Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.

[1]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Schneider,et al.  Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. , 2001, Seminars in oncology.

[3]  B. Wörmann,et al.  Trastuzumab and breast cancer. , 2001, The New England journal of medicine.

[4]  K. Carraway,et al.  Localization and modulation of ErbB receptor tyrosine kinases. , 2001, Current opinion in cell biology.

[5]  Z. Qian,et al.  Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. , 2001, Life sciences.

[6]  S. Reis,et al.  Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. , 2000, Circulation.

[7]  B. Lorell,et al.  Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. , 1999, Circulation.

[8]  Yosef Yarden,et al.  Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[9]  D. O’Rourke,et al.  Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers. , 1997, Proceedings of the Association of American Physicians.

[10]  M. Provinciali,et al.  Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA , 1997, Cancer Immunology, Immunotherapy.

[11]  S. Burden,et al.  Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses. , 1995, The EMBO journal.

[12]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[13]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[14]  Carmen Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[15]  D. Slamon,et al.  Radiolabeled antibody targeting of the HER-2/neu oncoprotein. , 1992, Cancer research.

[16]  Y. Yarden,et al.  Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Ullrich,et al.  Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.